Delivery Order SPE2DB22D3016-SPE2DB25FAYY4

Award Date 6/10/25
Potential Completion Date 6/11/25
Potential Value $5.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $57,780.90 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of May 19, 2025. The contract is not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
This is a $17,474.60 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a performance period extending through June 10, 2025. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,582.11 firm fixed-price delivery order is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract has an ultimate completion date of December 11, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a $9,966.60 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a performance period through May 20, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a $6,216.77 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a period of performance through May 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which...
This is a $4,318.89 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 syringes, a vaccine, to support military healthcare programs. It has an ultimate completion date of March 31, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle...
This is a $3,604.73 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a period of performance through February 7, 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves...
This is a $9,256.88 firm fixed price delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of GARDASIL 9 SYRINGE 0.5ML. The contract has an ultimate completion date of June 6, 2025 and is not set aside. Amerisourcebergen is a major pharmaceutical distributor that holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, allowing it to supply a wide range of pharmaceutical products and medical...
This is a $8,563.35 firm fixed-price delivery order awarded by the Defense Logistics Agency to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 vaccine syringes. The contract has an ultimate completion date of June 13, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, which...
This is a $11,485.83 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a period of performance through April 4, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB25FAYY4
    Delivery Order

This is a $5,814.84 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of June 11, 2025.

Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The contract award described is not designated as a set-aside.

Generated 9/14/25, 1:08 AM